A representative list of Mr. Levato’s recent life sciences capital markets transactions is set forth below:
- Merrill Lynch, Leerink and Stifel in a $312.0 million follow-on public offering for Zogenix, Inc.
- Morgan Stanley, Cowen and Jefferies in a $276.0 million follow-on public offering for Immunomedics, Inc.
- Merrill Lynch and Cowen in the $35.6 million U.S. IPO for TiGenix NV.
- Leerink and Cowen in the $60.0 million IPO for Bellerophon Therapeutics, Inc.
- Stifel and Piper Jaffray in the $66.0 million IPO for Conatus Pharmaceuticals Inc.
- Piper Jaffray and Stifel in the $58.5 million U.S. IPO for Innocoll AG.
- Stifel and JMP Securities in the $45.0 million IPO for Marinus Pharmaceuticals, Inc.
- Roth Capital Partners in a €13.0 million U.S. private placement for Oryzon Genomics, S.A.
- J.P. Morgan and Morgan Stanley in an $87.1 million follow-on public offering for NPS Pharmaceuticals, Inc.
- Leerink and Cowen in a $47.6 million U.S. follow-on public offering for Trillium Therapeutics Inc.
- Leerink and RBC Capital Markets in a $151.8 million U.S. follow-on public offering for Tekmira Pharmaceuticals Corporation
- Stifel in a $35.0 million U.S. private placement for Strongbridge Biopharma plc
- Medicrea International in a €20.0 million U.S. private placement
- Canaccord Genuity and JMP Securities in a $17.5 million U.S. follow-on public offering for Summit Therapeutics plc.
- Canaccord Genuity in a $37.4 million U.S. follow-on public offering and concurrent $32.7 million U.S. private placement for Neovasc Inc.
- Leerink and Cantor Fitzgerald in a $150.5 million U.S. follow-on public offering for Aurinia Pharmaceuticals Inc.
- Jefferies in a $63.0 million U.S. follow-on public offering for Compugen Ltd.
- BMO Capital Markets and Canaccord Genuity in a $42.7 million U.S follow-on public offering for VBI Vaccines Inc.
- Canaccord Genuity in a $50.3 million U.S. follow-on public offering for Novadaq Technologies Inc.
